Ctrl K
Last 22 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -22.14 | — | — | — | — | — | — | — | — | — | — | 53.80 | 15.26 | 17.40 | 330.41 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | 132.58 | — | 0.54 | 2.35 | 3.11 | 3.85 | 7.28 | 27.61 | 1193.99 | — | — | — | — |
| — | — | — | — | — | — | — | — | +4164.4% | — | -92.5% | -91.5% | -99.7% | — | — | — | — | — | — | — | — | |
| P/B Ratio | 10.50 | 8.35 | 5.63 | 3.74 | 3.82 | 3.40 | 1.51 | 1.57 | 1.12 | 0.49 | 0.59 | 2.35 | 3.05 | 3.92 | 5.90 | 7.10 | 11.44 | 5.82 | 2.75 | — | — |
| — | +145.3% | +273.5% | +137.8% | +239.8% | +588.1% | +153.6% | -33.0% | -63.2% | -87.4% | -89.9% | -66.9% | -73.3% | -32.7% | +114.2% | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | 19.30 | — | 45.40 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 95.37 | 15.07 | 15.50 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | 110.21 | 15.31 | 15.72 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 100.0% | -94.5% | 845.5% | -31.3% | 91.4% | 94.9% | 94.3% | 92.6% | 87.1% | 50.1% | — | — | — | — |
| — | — | — | — | — | — | — | +9.4% | -199.5% | +796.4% | -133.8% | +4.9% | +89.3% | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | 6113.4% | -18187.7% | 5223.4% | -137.8% | 1.8% | 18.2% | 20.6% | -2.9% | -203.8% | -15849.6% | — | — | — | — |
| — | — | — | — | — | — | — | +342713.0% | -99873.1% | +25295.7% | -4693.6% | +100.9% | +100.1% | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | 5646.0% | -17476.9% | 7106.5% | -134.0% | 4.4% | 20.3% | 22.5% | 2.2% | -195.1% | -15581.4% | — | — | — | — |
| — | — | — | — | — | — | — | +129324.5% | -86002.4% | +31519.8% | -6185.4% | +102.2% | +100.1% | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -61.6% | -17.0% | -14.3% | -10.4% | -13.8% | -22.4% | -19.6% | -20.8% | -31.8% | -24.8% | -31.3% | 1.1% | 5.2% | 6.0% | 0.5% | -17.6% | -31.9% | -24.9% | -106.6% | — | — |
| — | +24.5% | +27.2% | +50.2% | +56.7% | +9.6% | +37.4% | -1972.8% | -712.1% | -515.5% | -7008.2% | +106.3% | +116.3% | +124.0% | +100.4% | — | — | +90.8% | — | — | — | |
| ROA | -55.0% | -15.6% | -13.2% | -9.5% | -12.3% | -20.0% | -17.4% | -16.9% | -24.9% | -19.4% | -25.4% | 1.0% | 4.5% | 5.1% | 0.4% | -14.9% | -26.4% | -21.6% | -25.2% | -24.0% | -17.7% |
| — | +22.2% | +24.1% | +43.8% | +50.5% | -3.2% | +31.6% | -1857.6% | -649.4% | -478.5% | -6558.1% | +106.4% | +117.2% | +123.7% | +101.6% | +37.9% | -49.0% | — | +58.7% | — | — | |
| ROIC | -132.2% | -28.0% | -48.9% | -27.8% | -23.6% | -24.8% | -24.4% | -28.2% | -35.9% | -23.1% | -43.1% | 0.5% | 6.5% | 7.8% | -0.6% | -20.4% | -46.7% | -30.1% | -26.0% | — | — |
| — | -12.7% | -100.5% | +1.3% | +34.1% | -7.6% | +43.4% | -5498.2% | -651.6% | -395.6% | -7292.8% | +102.6% | +113.9% | +125.9% | +97.8% | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.04 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.05 | 0.04 | 0.03 | — | — |
| — | -38.1% | +200.5% | +62.3% | +36.6% | +195.5% | -39.7% | +23.0% | +14.8% | -12.2% | -30.6% | -47.0% | -75.7% | -62.7% | -45.0% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 1.90 | 0.25 | 0.26 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 14.27 | 12.12 | 17.85 | 14.27 | 13.70 | 8.72 | 12.05 | 6.67 | 4.55 | 4.66 | 4.48 | 5.66 | 9.52 | 6.67 | 7.54 | 8.20 | 5.27 | 7.96 | 9.58 | 6.03 | 8.58 |
| — | +38.9% | +48.1% | +113.9% | +201.2% | +87.1% | +169.1% | +17.7% | -52.2% | -30.1% | -40.6% | -30.9% | +80.4% | -16.2% | -21.3% | +35.9% | -38.5% | — | +414.7% | — | — | |
| Quick Ratio | 14.27 | 12.12 | 17.85 | 14.27 | 13.70 | 8.72 | 12.05 | 6.67 | 4.55 | 4.66 | 4.48 | 5.20 | 8.81 | 6.28 | 7.28 | 7.99 | 5.26 | 7.96 | 9.58 | 6.03 | 8.58 |
| — | +38.9% | +48.1% | +113.9% | +201.2% | +87.1% | +169.1% | +28.3% | -48.3% | -25.8% | -38.5% | -35.0% | +67.5% | -21.1% | -24.0% | +32.4% | -38.7% | — | +414.7% | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 22 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AMLX stock.
Amylyx Pharmaceuticals, Inc.'s current P/E is -22.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Amylyx Pharmaceuticals, Inc.'s business trajectory between earnings reports.